Our group participates in NCI's Co-Clinical Imaging Research Resource Program (CIRP). This consortium consists of multiple sites with a common goal of developing quantitative imaging resources for therapeutic co-clinical trials.
Our resource, PET imaging resource to enhance delivery of individualized cancer therapeutics (PREDICT), is focused on PET imaging and radiotracers of glutamine metabolism. The overarching vision for PREDICT is to develop and validate a suite of quantitative imaging tools that facilitate the discovery and optimization of novel, predictive gene expression signatures. PREDICT centers on a parallel co-clinical trial of patients with colorectal cancer (CRC) and patient-derived xenograft (PDX) mouse models of CRC. Imaging is performed using 11C-glutamine/18F-4-fluoro-glutamine and 18F-FSPG. We are correlating the imaging data to treatment response as well as biological correlates such as genetics (RNA-Seq) and immunohistochemistry. We are also developing protocols for standardization of PET in preclinical imaging studies.
This website contains information about the research and members of the MD Anderson Co-Clinical Imaging Research Resource Program. Protocols detailing methods for quantitative preclinical PET imaging and generation and storage of subcutaneous and orthotopic PDX models are under development. Data including patient demographics, PDX models, PET images, treatment response, and correlative biology (RNA-seq and immunohistochemistry) will be accessible through the MIRACCL site when available.
H. Charles Manning, Ph.D.
Professor, Department of Cancer Systems Imaging
Director, Cyclotron Radiochemistry Facility
Scientific Director, Center for Advanced Biomedical Imaging (CABI)
Sr. Administrative Assistant